GlassScriptPhysician profile
Yvette J Dancel
NPI 1780309252
$1,474.51
in general payments reported to CMS, 2019-2025
22 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $272 · 2024: $832 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.36 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $451.20 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $225.43 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.98 | 2023-2024 | Caplyta |
| Axsome Therapeutics, INC. | $104.91 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $76.93 | 2024-2025 | Airsupra |
| Lilly USA, LLC | $52.32 | 2025 | Kisunla |
| Sage Therapeutics, LLC | $46.46 | 2024 | |
| Neurocrine Biosciences, INC. | $35.40 | 2024 | Ingrezza |
| Novo Nordisk INC | $33.90 | 2025 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $30.43 | 2024-2025 | Austedo Xr, Austedo Xr |
| Exact Sciences Corporation | $28.95 | 2025 | Cologuard Collection Kit |
| Alkermes, INC. | $21.46 | 2023 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $19.97 | 2024 | |
| Sumitomo Pharma America, INC. | $18.20 | 2025 | Gemtesa |
| Pfizer INC. | $18.01 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16.66 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $16.49 | 2023 | Bexsero, Pediarix |
| Eisai INC. | $16.21 | 2025 | |
| Astellas Pharma US INC | $15.76 | 2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $15.39 | 2025 | Nuzyra |
| Lundbeck LLC | $14.98 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $13.47 | 2023 | Hetlioz, Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Dancel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.